|

Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers

RECRUITINGPhase 4Sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Actively Recruiting
PhasePhase 4
SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine
Started2026-07-10
Est. completion2029-03-30
Eligibility
Age50 Years – 90 Years
Healthy vol.Accepted

Summary

This study aims to evaluate the therapeutic efficacy of Lecanemab in patients with Alzheimer's disease. The researchers will use a novel detection method based on mesoporous gold electrode surface-enhanced electrochemiluminescence (ECL) to monitor specific biomarkers in the patients' plasma. By tracking changes in these biomarkers, the study seeks to determine how effectively Lecanemab treats the disease and to validate this new ECL-based monitoring system as a useful tool for clinical assessment.

Eligibility

Age: 50 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's dementia.
2. Age between 50 and 90 years (inclusive).
3. Confirmed presence of amyloid pathology (positive amyloid PET scan or CSF biomarkers).
4. Mini-Mental State Examination (MMSE) score between 22 and 30.
5. Clinical Dementia Rating (CDR) global score of 0.5 or 1.
6. Stable dose of allowed concomitant medications for at least 4 weeks prior to screening.
7. Willing and able to comply with the study procedures, including blood draws for ECL monitoring.
8. Signed informed consent form.

Exclusion Criteria:

1. Significant neurological disorders other than Alzheimer's disease (e.g., stroke, Parkinson's disease).
2. History of brain hemorrhage, microbleeds, or superficial siderosis on MRI.
3. Use of anticoagulants that cannot be safely interrupted.
4. Severe systemic diseases (e.g., severe heart failure, uncontrolled diabetes) that may interfere with the study.
5. Known hypersensitivity to Lecanemab or any excipients.
6. Pregnant or breastfeeding women.
7. Participation in another interventional clinical trial within the last 30 days.

Conditions2

Alzheimer DiseaseAlzheimer's Disease

Interventions1

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.